Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 6, 2005, Pages 603-609

  Oman M ^a   Lundqvist, S ^a   Gustavsson, B ^b   Hafström, Lo ^b   Naredi, P ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 fluorouracil; Intraperitoneal chemotherapy; Leucovorin; Pancreas cancer; Pharmacokinetics; Vasopressin

Indexed keywords

FLUOROURACIL; FLURABLASTIN; FOLINIC ACID; GEMCITABINE; LYPRESSIN; OXALIPLATIN; PEMETREXED; TIPIFARNIB; VASOPRESSIN;

ABDOMINAL PAIN; ABDOMINAL PRESSURE; ADULT; AGED; ALOPECIA; ANALYTIC METHOD; ANEMIA; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG INSTILLATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PANCREAS CANCER; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TIME; TOXICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; FEMALE; FLUOROURACIL; HEMOSTATICS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PALLIATIVE CARE; PANCREATIC NEOPLASMS; SURVIVAL RATE; VASOPRESSINS;

EID: 26444448492     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1012-5     Document Type: Article

References (27)

1. Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455
2. Oliani C, Padovani M, Manno P, Barana D, Falconi M, Bassi C, Cavallini G, Pederzoli P, Getto GL (2004) Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Res 24:2107
3. Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A, Schulz J, Hossfeld DK (2004) Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience. Anticancer Drugs 15:575
4. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez RJ, Ma Y, Von Hoff D (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430
5. Novarino A, Chiappino I, Bertelli GF, Heouaine A, Ritorto G, Addeo A, Bellone G, Merlano M, Bertetto O (2004) Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 15:474
6. Louvet C, Labianca R, Hammel P, Lledo G, De Braud F, Andre T, Cantore M, Ducreux M, Zaniboni A, De Gramont A (2004) GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III. ASCO 2004 Proc # 4008
7. Permert J, Hafstrom L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 40:361
8. Mahteme H, Larsson B, Sundin A, Khamis H, Graf W (2004) Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery, an autoradiographic study in the rat. Eur J Cancer 40:142
9. Lindner P, Heath DD, Shalinsky DR, Howell SB, Naredi P, Hafstrom L (1993) Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin and etoposide. Surg Oncol 2:105
10. Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916
11. Kuzuya T, Yamauchi M, Ito A, Hasegawa M, Hasegawa T, Nabeshima T (1994) Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 46:685
12. Oman M, Blind PJ, Naredi P, Gustavsson B, Hafstrom LO (2001) Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. Eur J Surg Oncol 27:477
13. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28:235
14. Welt FG, Rutlen DL (1991) Effect of vasopressin on systemic capacity. Am J Physiol 261:H1494
15. Lindner P, Heath D, Howell S, Naredi P, Hafstrom L (1996) Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. Clin Cancer Res 2:311
16. Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: McLeod CM (ed) Evaluation of chemotherapeutic agents in cancer. Columbia University Press, New York, pp 191
17. Gustavsson B, Baldesten A, Hasselgren PO, Almersjo O (1979) New assay of 5-fluorouracil in serum by isotachophoresis. J Chromatogr 179:151
18. Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M (2003) High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 65:108
19. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882
20. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Allen J, Tempero MA (2004) A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa). ASCO 2004 Proc # 4219
21. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403
22. Richards DA, Kindler HL, Oettle H, Ramanathan R, van Laethem JL, Peeters M, Fuchs M, John W, Arning M, Von Hoff D (2004) A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. ASCO 2004 Proc # 4007
23. Brennan MF, Kinsella TJ, Casper ES (1993) Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles & Practice of Oncology. JB Lippincott Co., Philadelphia, pp 849
24. Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE (1979) Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. Am J Roentgenol 133:221
25. El Malt M, Ceelen W, van Den BC, Cuvelier C, Van Belle S, De Neve W, de Hemptinne B, Pattyn P (2001) Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil. Int J Cancer 96:297
26. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT Jr, Myers CE (1980) Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567
27. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C (2002) Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 20:1683